Gastroenterology and Hepatology最新文献

筛选
英文 中文
Fibrate-OCA (Fi-OCA) Study - A Global Snapshot of PBC Practice Around the Globe.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Fibrate-OCA (Fi-OCA) Study - A Global Snapshot of PBC Practice Around the Globe.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 12","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Association Between IBS Quality of Life Score and Symptoms of Abdominal Pain, Bloating, and Cramping in IBS-C: A Pooled Phase 3 Trial Correlation Analysis.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"An Association Between IBS Quality of Life Score and Symptoms of Abdominal Pain, Bloating, and Cramping in IBS-C: A Pooled Phase 3 Trial Correlation Analysis.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 9","pages":"11-12"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of Lean MASH and MASLD.
Gastroenterology and Hepatology Pub Date : 2024-12-01
Vincent Wong
{"title":"Overview of Lean MASH and MASLD.","authors":"Vincent Wong","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12","pages":"745-747"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 10","pages":"12-13"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"15-16"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or >5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or >5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With MASLD in a Real-World Setting Is Associated With Slower Disease Progression and Lower All-Cause Mortality.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With MASLD in a Real-World Setting Is Associated With Slower Disease Progression and Lower All-Cause Mortality.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"10-11"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 10","pages":"10-12"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients With Irritable Bowel Syndrome With Constipation From the IBS in America 2024 Real-World Survey Experience Burdensome Symptoms Beyond Constipation.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Patients With Irritable Bowel Syndrome With Constipation From the IBS in America 2024 Real-World Survey Experience Burdensome Symptoms Beyond Constipation.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 9","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44.
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 10","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信